Navigation Links
New Drug Promising Against Rheumatoid Arthritis
Date:6/29/2009

Golimumab might help where similar drugs failed, research finds

MONDAY, June 29 (HealthDay News) -- The immunosuppressive drug golimumab shows promise in treating rheumatoid arthritis patients who don't respond to other drugs, according to a new study. Golimumab is from the family of drugs called tumor necrosis factor-a (TNF-a) inhibitors.

The new study included 461 patients in 10 countries who were randomly selected to receive either injections of placebo, 50 milligrams of golimumab or 100 milligrams of golimumab. The injections were given every four weeks for 24 weeks.

After 14 weeks, 35 percent of patients taking 50 milligrams of golimumab and 38 percent of those taking 100 milligrams of the drug achieved a 20 percent or higher improvement in American College of Rheumatology criteria for assessment of rheumatoid arthritis (ACR 20), compared with 18 percent of patients taking the placebo.

The study also found that among the 58 percent of patients who had discontinued a previous TNF-a inhibitor treatment because it wasn't effective, ACR 20 was achieved by 36 percent of patients taking 50 milligrams of golimumab, 43 percent of those taking 100 milligrams of golimumab and 18 percent of those in the placebo group.

After 24 weeks of treatment, serious adverse events were recorded in five percent of patients taking 50 milligrams of golimumab, four percent of those taking 100 milligrams of the drug and in 10 percent of patients on placebo.

"Golimumab reduces the signs and symptoms of active rheumatoid arthritis and improves physical function in patients who had previously received TNF-a inhibitors, which suggests that switching patients from one TNF-a inhibitor to golimumab is effective and generally well-tolerated," wrote Josef Smolen of the Medical University of Vienna and Hietzing Hospital in Vienna, Austria, and colleagues.

In a commentary, Dr. Yusuf Yazici of New York University Hospital for Joint Diseases, New York City, said that "for those patients who have failed or had an inadequate response to etanercept, infliximab, adalimumab or abatacept, golimumab might be a good option."

The study, which was funded by drug makers Centocor, Inc. and Schering- Plough, appears online June 29 inThe Lancet.

Rheumatoid arthritis is a chronic inflammatory disease that affects about 1.3 million people in the United States. TNF-a inhibitors are widely used to treat the disease, but 30 to 50 percent of patients treated with these drugs are intolerant or have an inadequate response to the drugs. Prior to this study, no controlled trials had examined whether patients who don't respond to one TNF-a inhibitor might respond to another.

More information

The Arthritis Foundation has more about rheumatoid arthritis.



-- Robert Preidt



SOURCE: The Lancet, news release, June 28, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Respiratory Rally a Promising Practice in the Fight Against Chronic Disease
2. Promising Therapy for Prostate Cancer
3. Promising biomarker and candidate tumor suppressor gene identified for colorectal cancer
4. AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure
5. 17 of Americas Most Promising Scientists Selected as 2009 Pew Scholars in the Biomedical Sciences
6. CORRECTION: Viral Genetics Pursues Promising New Therapy for Lyme Disease With Grant from Time for Lyme, Inc.
7. Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
8. Triple drug combination is promising option to treat metastatic HER2+ breast cancer
9. Aleres Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives
10. New drug shows promising results for psoriatic arthritis
11. Will Obamas Stem Cell Announcement Doom Promising Adult Stem Cell Research?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Promising Against Rheumatoid Arthritis
(Date:5/31/2016)... , ... June 01, 2016 , ... A book about ... New Renaissance ” (published by Balboa Press AU) attempts to give readers the courage ... , β€œThe Divine has inspired and guided me throughout my life to learn ...
(Date:5/31/2016)... Hollywood, Fl (PRWEB) , ... May 31, 2016 ... ... the doors to its new Concussion Clinic serving South Florida. , The ... sports medicine, pediatric neurology, pediatric physical medicine and rehabilitation, pediatric neuropsychology and also ...
(Date:5/31/2016)... (PRWEB) , ... June 01, 2016 , ... ... β€œ Psoriasis and smoking: links and risks ”. , As corresponding author Professor ... on the relation between smoking habits and psoriasis. Smoking influences the onset and ...
(Date:5/31/2016)... ... ... adults often find themselves reaching for a cup of coffee, an energy drink, or even ... is a cup of Matcha green tea. Matcha is a premium green tea powder made ... early June to mid-July, when the leaves are the most tender. , Matcha ...
(Date:5/31/2016)... ... 2016 , ... Splashtop Inc., the worldwide leader in high performance cross-screen ... the leading provider of secure mobile remote access solution for Japan enterprises. ... access solution. Splashtop for CACHATTO will be available as an integrated add-on ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... , May 30, 2016 ... report "Healthcare Biometrics Market by Technology (Single-factor ... Multifactor, Multimodal), Application (Workforce Management), End User ... 2021", published by MarketsandMarkets, the market is ... 2021 from USD 1,182.6 Million by 2016, ...
(Date:5/30/2016)... 30, 2016 LifeScienceIndustryResearch.com adds ... research report with comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharma company focused on the highly lucrative ... a substantial pipeline of potential first-in-class or best-in-class ... are in development with strategic partners. HCM,s profitable ... fast-growing domestic market. We expect progress of the ...
Breaking Medicine Technology: